10.22376/ijpbs.2019.10.1.p1-12 Volume 13 Issue 4 October - December Type 2 Diabetes Mellitus(T2DM) is a chronic progressive disease characterized by hyperglycemia and progressive dysregulation leading to microvascular and macrovascular complications. Glucagon-like peptide 1 (GLP-1) based therapy is an established treatment option for the management of type 2 diabetes mellitus (T2DM) and is recommended early in the treatment algorithm owing to glycaemic efficacy, weight reduction, and favourable cardiovascular outcomes. A glucose-dependent insulinotropic polypeptide (GIP), on the other hand, was thought to have no potential as a glucose-lowering therapy because of observations showing no insulinotropic effect from supraphysiological infusion in people with T2DM. However, emerging evidence has illustrated that, co-administration of GLP-1 and GIP has a synergistic effect, resulting in significantly increased insulin response and glucagonostatic response, compared with separate administration of each hormone. These observations have led to developing a dual GIP/GLP-1 receptor agonist, known as a 'twincretin' called Tirzepatide. In this paper, we have reviewed different clinical trials to evaluate the efficacy and safety of Tirzepatide over conventional antidiabetic drugs like Metformin and newer GLP1-receptor agonists in the treatment of T2DM. We consider the reduction of glycated hemoglobin (HbA1C) and body weight as our objectives in our study. lessThan b greaterThan In lessThan /b greaterThan May 2022, FDA approved Tirzepatide for the treatment of T2 DM, which is a novel dual GIP/GLP-1 receptor agonist formulated as a synthetic peptide containing 39 amino acids, based on the native GIP sequence. The newly approved drug has shown excellent results in lowering blood glucose and weight loss. Pre-clinical trials and Phase 1, Phase 2, and Phase 3 clinical trials compared Tirzepatide vs Placebo or GLP-1 receptor agonists which concluded that Tirzepatide potent glucose-lowering and weight loss causing agent with adverse effects comparable to those of established GLP-1 receptor agonists. It is too early to comment on the long-term efficacy, safety, and cardiovascular outcomes of tirzepatide. Dr. Avula Naveen ,Dr. Mr Sravani and Dr .Syed Ilias Basha3 Tirzepatide, Glucagon-Like Peptide 1; Gastric Inhibitory Peptide; Incretin Hormone; Type 2 Diabetes Mellitus. 7-15